pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·24m ago·1 min read
save

AI bio startup Boltz raises $110M Series A

LONDON — Less than a year after launching from stealth with $28 million, the AI bio startup Boltz has raised a $110 million Series A round, its leaders exclusively told Endpoints News. The ...

Nov 18, 2026·read at Endpoints ↗

Boltz's leadership team (L-R): Jeremy Wohlwend, Gabriele Corso and Saro Passaro November 18, 2026 07:00 AM EST FinancingAI Ex­clu­sive: Boltz rais­es $110M as us­age of its AI drug de­sign soft­ware jumps 50-fold Andrew Dunn Senior Biopharma Correspondent LON­DON — Less than a year af­ter launch­ing from stealth with $28 mil­lion, the AI bio start­up Boltz has raised a $110 mil­lion … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
95 words · retrieved 6m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 40m agoMerck ends the sorry saga of BTK inhibitor it got from ArQuleEndpoints
  • 11h ago#CTAD26: Biogen’s tau drug slows Alzheimer’s more after nearly two yearsEndpoints
  • 11h agoWhite House pulls FDA nominee Overton amid uncertain Senate supportEndpoints
  • 15h agoFDA flags potential VEGF-related safety concern in Summit rejection letterEndpoints
  • 15h agoBeren wins FDA approval for long-studied rare disease drugEndpoints